2 recruiting, 1 completed, 1 not yet recruiting. 4 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Recruiting 2, Completed 1, Not yet recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow Community Acquired Pneumonia (CAP): new trials by email Literature Review of Community Acquired Pneumonia (CAP) trials Research Report on Community Acquired Pneumonia (CAP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP) | Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 168 | 2026-04-08 | 2026-05-11 |
| Local Antibiotic Delivery for Community Acquired Pneumonia Levofloxacin, Placebo - Community Acquired Pneumonia (CAP) | Phase 2 / Phase 3 | Not yet recruiting | Copenhagen Respiratory Research | 36 | 2025-03-04 | 2025-03-10 |
| Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide - Respiratory Tract Diseases, Influenza (Pandemic) | Phase 3 | Recruiting | UMC Utrecht | 20000 | 2016-04-11 | 2026-11-04 |
| The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP) Azithromycin - Community Acquired Pneumonia (CAP) | Phase 3 | Completed | Pfizer | 102 | 2009-02-01 | 2011-05-19 |
Community-Acquired Pneumonia (4) · Asthma (1) · COVID-19 (1) · Community-Acquired Infections (1) · Inflammation (1) · Influenza, Human (1) · Lung Diseases (1) · Plaque, Atherosclerotic (1) · Pneumonia (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Tract Diseases (1) · Respiratory Tract Infections (1)
Infections (4) · Community-Acquired Infections (3) · Pneumonia (3) · Respiratory Tract Diseases (3) · Respiratory Tract Infections (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Bronchial Diseases (1) · Chronic Disease (1) · Coronaviridae Infections (1) · Coronavirus Infections (1) · Disease Attributes (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1)
Levofloxacin (2) · Amoxicillin-Potassium Clavulanate Combination (1) · Angiotensin Receptor Antagonists (1) · Angiotensin-Converting Enzyme Inhibitors (1) · Ascorbic Acid (1) · Aspirin (1) · Azithromycin (1) · Captopril (1) · Ceftaroline (1) · Ceftazidime (1) · Ceftriaxone (1) · Clopidogrel (1) · Congresses as Topic (1) · Cysteamine (1) · Enalapril (1)
Copenhagen Respiratory Research (1) · Ottawa Heart Institute Research Corporation (1) · Pfizer (1) · UMC Utrecht (1)
Canada (2) · Japan (2) · Australia (1) · Belgium (1) · Colombia (1) · Croatia (1) · Czechia (1) · Estonia (1) · Finland (1) · France (1) · Germany (1) · Hungary (1) · India (1) · Ireland (1) · Israel (1)
Colin McArthur, Dr (1) · Derek Angus, Prof (1) · Jens-Ulrik S. Jensen, Professor, MD, phD (1) · John Marshall, Prof (1) · Kevin Boczar, MD (1) · Lennie Derde, MD (1) · Luis Felipe Reyes, MD, MSc, PhD (1) · Marc Bonten, Prof (1) · Steve Webb, Prof (1)
PMID 24477328, PMID 32267771, PMID 32876697, PMID 33394942, PMID 33509275, PMID 33631065, PMID 34251506, PMID 34351721, PMID 34351722, PMID 34473343, PMID 34606578, PMID 35315874, PMID 36525245, PMID 36942550, PMID 36967714, PMID 37039790, PMID 37256341, PMID 37489818, PMID 37877585, PMID 37888913, PMID 40261382, PMID 40360262, PMID 41781043, PMID 42823695
2015 (1), 2023 (1)